StockNews.AI
LUNG
StockNews.AI
187 days

Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day

1. Pulmonx will participate in a Citi Medtech event on February 27, 2025. 2. The company is a leader in treatments for severe lung diseases like COPD. 3. Pulmonx's Zephyr Valve is a breakthrough device, enhancing patient quality of life. 4. The Valve is in over 25 countries and adheres to global treatment guidelines.

3m saved
Insight
Article

FAQ

Why Bullish?

Increased exposure from the event can positively impact investor interest, similar to past Medtech presentations boosting stocks.

How important is it?

The participation in a prominent industry event indicates growth potential, impacting LUNG's market perception.

Why Short Term?

The upcoming event may create immediate investor optimism, similar to previous announcement effects.

Related Companies

COPDMEDTPHAR
February 13, 2025 16:05 ET  | Source: Pulmonx Corporation REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 27, 2025, at 8:00 AM PT / 11:00 AM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com. ContactBrian JohnstonGilmartin Groupinvestors@pulmonx.com

Related News